$29.46
4.06% yesterday
NYSE, Apr 15, 10:18 pm CET
ISIN
US4330001060
Symbol
HIMS

Hims & Hers Health Inc. Stock price

$29.46
-5.23 15.08% 1M
+6.66 29.21% 6M
+5.28 21.84% YTD
+16.24 122.84% 1Y
+24.40 482.21% 3Y
+19.59 198.48% 5Y
+19.66 200.61% 10Y
NYSE, Closing price Tue, Apr 15 2025
+1.15 4.06%
ISIN
US4330001060
Symbol
HIMS
Industry

Key metrics

Market capitalization $6.55b
Enterprise Value $6.26b
P/E (TTM) P/E ratio 55.09
EV/FCF (TTM) EV/FCF 31.54
EV/Sales (TTM) EV/Sales 4.24
P/S ratio (TTM) P/S ratio 4.43
P/B ratio (TTM) P/B ratio 13.65
Revenue growth (TTM) Revenue growth 69.33%
Revenue (TTM) Revenue $1.48b
EBIT (operating result TTM) EBIT $68.00m
Free Cash Flow (TTM) Free Cash Flow $198.33m
Cash position $300.25m
EPS (TTM) EPS $0.53
P/E forward 48.60
P/S forward 2.81
EV/Sales forward 2.68
Short interest 29.55%
Show more

Is Hims & Hers Health Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Hims & Hers Health Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

6x Buy
38%
8x Hold
50%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Hims & Hers Health Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,477 1,477
69% 69%
100%
- Direct Costs 437 437
162% 162%
30%
1,039 1,039
47% 47%
70%
- Selling and Administrative Expenses 954 954
30% 30%
65%
- Research and Development Expense - -
-
-
85 85
422% 422%
6%
- Depreciation and Amortization 17 17
80% 80%
1%
EBIT (Operating Income) EBIT 68 68
289% 289%
5%
Net Profit 126 126
635% 635%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Hims & Hers Health Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hims & Hers Health Inc. Stock News

Positive
MarketBeat
6 days ago
One of the more hotly debated stocks in the market, Hims & Hers Health NYSE: HIMS, recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly's NYSE: LLY blockbuster weight loss drug.
Positive
The Motley Fool
13 days ago
Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.
Negative
Investors Business Daily
14 days ago
Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide. The post Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch appeared first on Investor's Business Daily.
More Hims & Hers Health Inc. News

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Head office United States
CEO Andrew Dudum
Employees 1,637
Founded 2017
Website www.forhims.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today